Impact of HIV and Its Treatment on Reverse Cholesterol Transport

The Alfred44 enrolled

Overview

To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport, endothelial function and intima-media thickness in HIV patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

HIV Infections

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male patients with HIV infection (3 groups of 50 patients each) * HIV infected patients, naïve to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months) * HIV-infected patients, PI naïve, initiating therapy with PI-containing HAART (ARV naïve or NNRTI experienced changing to PI regimen) * HIV-infected patients naïve to ARV therapy, initiating NNRTI-containing regimen Exclusion criteria * Treatment with any form of lipid lowering drugs, including fish oils. * Body Mass Index greater than 27.

Locations (1)

Alfred Hospital and Baker Heart Research Institute

Melbourne, Victoria, Australia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.